The significance of flow cytometric analysis in multicenter clinical trials in pediatric hematological malignancies

Abstract

The hematological malignancy is very rare, however it is as diverse as those in adults. Based on these characteristics, multicenter clinical trial is necessary to provide high quality diagnosis and treatment to patients. We have performed

diagnosis and classifi cation by fl ow cytometry (FCM) method. As a result, it became applicable not only to the diagnosis of each hematopoietic tumor case but also to the characteristics of the malignancy, the prognosis prediction, the target treatment, and it became possible to more clearly characterize the hematopoietic tumor. In this paper, we analyzed 652

cases diagnosed in Osaka University from August 2011 to March 2017. The ALL subtype was detected at the same frequency as previously reported. We were able to detect CRLF 2, NG 2 as part of the research. DNA index was also examined, and ploidy could be well detected. FCM detects the protein expressed on the surface of various cells, not only examines the number and ratio, it is also possible to study the characteristic and function of the expressed protein on the cells. The procedure is simple and can be diagnosed and quantifi ed quickly. Even in the genome era, the FCM, which can search for the type and amount of protein expressed on tumor or normal cells at once, is still an excellent method, and it is necessary to provide important knowledge.